CFM
DMRA

Catalyst Funds Management’s Damora Therapeutics DMRA Stock Holding History

Catalyst Funds Management’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-17,293
Closed -$448K – 744
2026
Q1 		$448K Buy
+17,293
New +$444K 0.08% 270

Other funds holding DMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

Catalyst Funds Management's DMRA Position: Q2 2026 in Review

Catalyst Funds Management sold out of Damora Therapeutics (DMRA) in Q2 2026, closing a stake of 17,293 shares — an estimated $448K sold.

Catalyst Funds Management first reported a position in DMRA in Q1 2026 and held it in 1 quarter. The position peaked at $448K in Q1 2026. 104 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

  • Catalyst Funds Management reported no remaining Damora Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Catalyst Funds Management sold 17,293 Damora Therapeutics shares in Q2 2026, an estimated $448K.
  • Catalyst Funds Management first reported a position in Damora Therapeutics in Q1 2026 and held it in 1 quarter.
  • Catalyst Funds Management's Damora Therapeutics position peaked at $448K in Q1 2026.
  • 104 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.